The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan
Open accessAbstract
STRUCTURED ABSTRACT Background: Natriuretic peptides are substrates of neprilysin; hence B-type natriuretic peptide (BNP) concentrations rise with neprilysin inhibition. Thus, the clinical validity of measuring BNP in sacubitril/valsartan-treated patients has been questioned, and use of N-terminal pro-BNP (NT-proBNP) has been preferred and recommended. Objectives: To determine the prognostic performance of BNP measurements before and during treatment with sacubitril/valsartan. Methods: BNP and NT-proBNP were measured before and after 4–6 weeks, 8–10 weeks, and 9 months of treatment with sacubitril/valsartan in the PARADIGM-HF trial. We assessed the association of levels of these natriuretic peptides with the subsequent risk of cardiovascular death or hospitalization for HF. Results: Median BNP concentration (before treatment: 202 [Q1–Q3 126–335] ng/L) increased to 235 (Q1–Q3 128–422) ng/L after 8–10 weeks of treatment. A total of 141 (18%) patients experiencing a doubling and 49 (6%) experienced a tripling of BNP during the first 8–10 weeks of sacubitril/valsartan. In contrast, such striking increases in NT-proBNP following the use of the neprilysin inhibitor were extremely rare. Treatment with sacubitril/valsartan caused a rightward shift in the distribution of BNP when compared with NT-pro-BNP, but both peptides retained their prognostic accuracy (C-statistics of 63–67% for BNP and C-statistics of 64–70% for NT-proBNP) with no difference between the 2 biomarkers. Increases in both BNP and NT-proBNP during 8–10 weeks of sacubitril/valsartan were associated with worse outcomes (P=0.003 and P=0.005, respectively). Conclusions: Circulating levels of BNP may increase meaningfully early after initiation of sacubitril/valsartan. In comparison, NT-proBNP is less directly influenced by neprilysin inhibition, and thus may lead to less clinical confusion when measured within 8–10 weeks of drug initiation. However, during treatment, either biomarker predicts the risk of major adverse outcomes in patients treated with angiotensin receptor-neprilysin inhibitors. Clinical Trial Registration: Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; ClinicalTrials.gov Unique identifier: NCT01035255.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · cited 4×
“Manuscript received October 31, 2018; revised manuscript received Decemb long-term efficacy and safety of sacubitril/ valsartan compared with enalapril in patients with HF with reduced ejection fraction, as previously described (5,12).”
BackgroundMethodInfluentialSelf-citationYancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
Angiotensin-neprilysin inhibition in acute decompensated heart failure
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812851 · Cited by 1,260
Cited by
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.022 · Cited by 842
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Self-citation
Metadata
- Authors
- Myhre, P. L., Vaduganathan, M., Claggett, B., Packer, M., Desai, A. S., Rouleau, J. L., Zile, M. R., Swedberg, K., Lefkowitz, M., Shi, V., McMurray, J. J. V., & Solomon, S. D.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 73
- Issue
- 11
- Pages
- 1264-1272
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2918599246
- Cited by
- 203
- References
- 4
- FWCI
- 18.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. https://app.cochat.ai/papers/10.1016/j.jacc.2019.01.018
- The paper
- Myhre, P. L., Vaduganathan, M., Claggett, B., Packer, M., Desai, A. S., Rouleau, J. L., Zile, M. R., Swedberg, K., Lefkowitz, M., Shi, V., McMurray, J. J. V., & Solomon, S. D. (2019). B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2019.01.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.